Literature DB >> 27826164

How Should Canadian Pharmacy Departments Utilize Idarucizumab?

Kirsten Tangedal1, William Semchuk1, Jennifer Bolt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27826164      PMCID： PMC5085331          DOI： 10.4212/cjhp.v69i5.1601

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  8 in total

Review 1.  The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis.

Authors:  Chatree Chai-Adisaksopha; Mark Crowther; Tetsuya Isayama; Wendy Lim
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

Review 2.  Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants.

Authors:  Aaron Liew; John W Eikelboom; Martin O'Donnell; Robert G Hart
Journal:  Can J Cardiol       Date:  2013-07       Impact factor: 5.223

3.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

4.  Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

Authors:  Stephan Glund; Joachim Stangier; Michael Schmohl; Dietmar Gansser; Stephen Norris; Joanne van Ryn; Benjamin Lang; Steven Ramael; Viktoria Moschetti; Fredrik Gruenenfelder; Paul Reilly; Jörg Kreuzer
Journal:  Lancet       Date:  2015-06-15       Impact factor: 79.321

5.  A specific antidote for dabigatran: functional and structural characterization.

Authors:  Felix Schiele; Joanne van Ryn; Keith Canada; Corey Newsome; Eliud Sepulveda; John Park; Herbert Nar; Tobias Litzenburger
Journal:  Blood       Date:  2013-03-08       Impact factor: 22.113

6.  Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.

Authors:  Benjamin A Steinberg; Sunghee Kim; Jonathan P Piccini; Gregg C Fonarow; Renato D Lopes; Laine Thomas; Michael D Ezekowitz; Jack Ansell; Peter Kowey; Daniel E Singer; Bernard Gersh; Kenneth W Mahaffey; Elaine Hylek; Alan S Go; Paul Chang; Eric D Peterson
Journal:  Circulation       Date:  2013-07-16       Impact factor: 29.690

Review 7.  Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents.

Authors:  Mark A Crowther; Theodore E Warkentin
Journal:  Blood       Date:  2008-02-28       Impact factor: 22.113

8.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

Authors:  Deborah M Siegal; John T Curnutte; Stuart J Connolly; Genmin Lu; Pamela B Conley; Brian L Wiens; Vandana S Mathur; Janice Castillo; Michele D Bronson; Janet M Leeds; Florie A Mar; Alex Gold; Mark A Crowther
Journal:  N Engl J Med       Date:  2015-11-11       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.